Clinical Trial Update: Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating loncastuximab tesirine in patients with relapsed or refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• High-grade B-cell Lymphoma

Drugs mentioned

• Zynlonta (loncastuximab tesirine)

Snippet

Sponsor: Istituto Clinico Humanitas | Conditions: Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma (HGBCL) | Phase 2 | Status: RECRUITING